Faron

We were thrilled to present the full phase 2 interim data from BEXMAB trial at the 66th American Society of Hematology (ASH) Annual Meeting earlier today! Key takeaways: ✅ 80% overall response rate in r/r MDS patients  ✅ Deep and durable responses: 70% achieved complete response (CR) / marrow complete remission (mCR) / partial response (PR) ✅ 4 patients advanced to receive a bone marrow transplant ✅ Median overall survival estimated at 13.4 months in r/r MDS population Faron will host a virtual webinar to discuss the full analysis of data today, on December 10, 2024, at 16.00 EET/9am ET/6am PT. To register for the event, please visit https://lnkd.in/dQgiAZ8Z The full poster containing the updated clinical data from the BEXMAB trial is available on Faron ‘s website at https://lnkd.in/ddpM9rCT #Faron #bexmarilimab #biotech #drugdevelopment #CancerResearch #Immunotherapy #ASH

Rise and shine from San Diego, ASH 2024! Yesterday was a big day for Faron as we presented our poster in Ash 2024, the world's largest and most comprehensive hematology event of the year. Our title for the poster presentation was Encouraging Efficacy of Bexmarilimab with Azacitidine in Relapsed or Refractory MDS in Bexmab Ph1/2 Study. The lead authors (in the picture from left) are Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki; & Dr. Amer Zeidan, MD, MBBS, MHS, Associate Professor of Medicine, Chief of Hematologic Malignancies Division, Director of Hematology Early Therapeutics Research, and leader of the clinical program and the Clinical Research Team for Leukemia and Myeloid Malignancies at Yale Cancer Center.   We are hosting a virtual webinar to discuss the full analysis of data later today, 10 December 2024 at 16.00 EET/9am ET/6am PT.   To register for the event visit the link in the post comments.   #Faron #bexmarilimab #biotech #drugdevelopment #CancerResearch #Immunotherapy #ASH

Greetings from San Diego, USA! Team Faron Juho Jalkanen MD, PhD, Elina Louramo & Petri Bono is exploring the world's largest and most comprehensive hematology event of the year – the ASH. The event is organized by the American Society of Hematology and held for the 66th time this year – what a remarkable journey for them!    The day was filled with inspiring encounters. Luckily the event can also be attended remotely from every corner of the world, as hematological diseases are a shared concern globally.   We are excited to be here and looking forward to our poster presentation tomorrow – stay tuned!   #Faron #bexmarilimab #biotech #drugdevelopment #CancerResearch #Immunotherapy #ASH

Today we announced that following interaction with UK Regulatory Authorities, our BEXMAB Study, investigating Faron’s wholly-owned #immunotherapy candidate #bexmarilimab in relapsed and refractory myelodysplastic syndrome patients (r/r MDS), has received regulatory approval to be conducted in the UK.    Additionally, bexmarilimab has received an Innovation Passport, under the Innovative Licensing and Access Pathway (ILAP) from the UK's Medicines and Healthcare products Regulatory Agency (MHRA), for the treatment of relapsed/refractory r/r MDS.   The ILAP will provide Faron with enhanced regulatory support from the MHRA and collaborative opportunities with health technology assessment bodies and other stakeholders, highlighting bexmarilimab’s potential to address critical unmet medical needs and positioning the therapy for faster development and potentially earlier access for patients.    Read the full press release here: https://lnkd.in/etcx3r8m     #Faron #biotech #drugdevelopment #oncology

Today, we announced new positive interim phase 2 readout data from our BEXMAB trial. ✨ Key Highlights: ✅ The new data confirmed our earlier positive Phase 1 & 2 findings ✅ 80% Objective Response Rate (ORR) in 20 MDS patients who are refractory or relapsed on HMA (r/r MDS) and have no effective treatment options (up from the ORR of 79% in the data published in May 2024). ✅ Estimated median overall survival (mOS) of 13.4 months, compared to the historical average of 5-6 months typically expected under standard of care. We will present the full data at the 66th ASH Annual Meeting in San Diego, CA, on December 9, 2024. Join us in a virtual webinar to discuss the full analysis of data on Tuesday, December 10, 2024 at 16.00 EET/9am ET. To register, please visit: BEXMAB Study Update To read the full release, please visit: https://lnkd.in/gtPS2m2r #Faron #bexmarilimab #biotech #drugdevelopment #CancerResearch #Immunotherapy #ASH2024 #ActivateYourBodyToDeactiveCancer

We recently announced a patent filing covering the use of soluble Clever-1 for inactivating T-cells to treat autoimmune diseases and inflammatory disorders. This is based on our findings which showed that Clever-1-positive macrophages and endothelial cells secrete a soluble form of Clever-1 which binds to T-cells and inactivates them. Faron and its researchers successfully identified this soluble part of Clever-1. Following this filing, we intend to utilise the soluble Clever-1 or fragments to design the optimal drug for treating autoimmune diseases, with the aim of expanding our pipeline beyond hematological cancers and solid tumor oncology. Read the full press release here: https://lnkd.in/emRYT23E #Faron #biotech #drugdevelopment #Macrophages 

Our CEO Juho Jalkanen MD, PhD, CFO Yrjö E K Wichmann, and Business Development Manager Elina Louramo are on the ground in Stockholm this week, attending EBD Group BIO-Europe, a conference bringing together over 5,500 professionals to foster innovation and partnerships within the biopharma community. Please reach out if you would like to connect with Faron’s team to learn more about #bexmarilimab, our wholly owned #immunotherapy candidate, and our strategy to maximise its potential for both patients and investors. #BIOEurope #Faron #biotech #drugdevelopment #oncology

What a great event! #ICYMI last week we hosted a Capital Markets Day, discussing the strong data continuing to build in our ongoing Phase I/II BEXMAB trial investigating Faron’s wholly-owned #immunotherapy candidate #bexmarilimab in relapsed and refractory myelodysplastic syndrome patients. We also provided an update on the progress of our partnering discussions and shared the progress we’ve made with our development plan for bexmarilimab's future potential in treating solid tumors.    Huge thanks to Dr. Juho Jalkanen MD, PhD, our CEO, for leading the event, alongside our CMO Dr. Petri Bono, CSO Dr. Maija Hollmén, Principal Investigator of the BEXMAB trial Dr. Mika Kontro, and Mr. Ralph Hughes, MSc, BSc, Senior Vice President at PharmaVentures.   Watch the full recording: https://lnkd.in/diRv8yWW #Faron #biotech #drugDevelopment

Faron hosts its Capital Markets Day today at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST). The management team will be joined by  Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki, and Mr. Ralph Hughes, MSc, BSc, Senior Vice President at PharmaVentures. Learn more in today’s press release: https://bit.ly/3YcaAXX And register to watch the webcast here: https://lnkd.in/diRv8yWW #Faron #biotech #drugdevelopment #oncology

Our CEO Dr. Juho Jalkanen MD, PhD is attending the Proactive One2One Biotech Investor Forum this evening in London, an event bringing together biotech companies and investors to explore investment opportunities and foster valuable connections.   Please reach out if you would like to hear more about #bexmarilimab, our wholly owned #immunotherapy candidate, for the treatment of myelodysplastic syndrome (MDS) patients that have failed a hypomethylating agent (HMA) which has recently been granted Fast Track Designation (FTD) by the FDA.   To register for the event, visit: https://lnkd.in/etvMswBw   #Forum #Investors #Faron #bexmarilimab #Biotech #DrugDevelopment